Lipids & metabolic liver disease
Metabolic dysfunction-associated fatty liver disease and the risk of incident chronic kidney disease: A 10-year prospective cohort study
Main finding · Incident CKDResult — go to the resultMultivariable-adjusted OR 1.25 95 % CI 1.11–1.40Authors' conclusion
CKD risk was associated with MAFLD presence, and gradually increased with the number of MAFLD metabolic components increased. Metabolic diseases might mediate the association between MAFLD-related GRS and CKD risk.
Study context
- Population
- Participants of the Dongfeng-Tongji (DFTJ) cohort; CKD defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m²8,843 with genotyping data
- Participants
- 10,817 participants
- Exposure
- MAFLD and non-alcoholic fatty liver disease (NAFLD) without MD vs non-FLD
- Outcome
- Incident CKD (eGFR <60 ml/min/1.73 m²)
- Follow-up
- ten-year follow-up
Main finding
Incident CKD
Multivariable-adjusted OR
1.25
95 % CI 1.11–1.40
By group
MAFLDvs non-FLD
multivariable-adjusted OR 1.25 (95 % CI 1.11–1.40)
As reported in the abstract
- Participants developing CKD
- 1,845
Observational data: associations, not effects.
Further findings
CKD risk by number of MAFLD co-existing metabolic dysfunction components
- Risk of CKD increased as number of components increased
- P for trend < 0.001
MAFLD-related genetic risk score (GRS), metabolic traits and CKD risk
- GRS positively associated with elevated blood pressure and elevated TG
- P < 0.05
- Share of GRS–CKD association mediated by elevated blood pressure
- 17.8 %
- Share of GRS–CKD association mediated by elevated TG
- 14.7 %
Original publication
Metabolic dysfunction-associated fatty liver disease and the risk of incident chronic kidney disease: A 10-year prospective cohort study. Diabetes Res Clin Pract. Published 2 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →